<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38784592</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Characterizing health-related quality of life and identifying disease predictors among patients suspected of having long COVID: an analysis of COMET-ICE clinical trial data.</ArticleTitle><Pagination><StartPage>1278106</StartPage><MedlinePgn>1278106</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1278106</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2024.1278106</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Long COVID affects health-related quality of life (HRQoL). Here, we investigate the extent to which symptoms experienced during the acute phase of COVID-19 are significant predictors of the presence of long COVID at 12&#x2009;weeks.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Post-hoc analysis of COMET-ICE trial data, which assessed sotrovimab vs. placebo for treatment of mild-to-moderate COVID-19 among high-risk patients. Patient-reported outcome measures were completed during the trial, including the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus), the 12-Item Short Form (SF-12) Hybrid questionnaire, and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). COVID-19 symptoms and impacts (measured by the FLU-PRO Plus) and HRQoL (measured by SF-12 Hybrid and WPAI:GH) were compared between the acute phase (Days 1-21 and 29) and long-COVID phase (at Week 12) among patients with and without long COVID based on COMET-ICE data. Subgroups experiencing long COVID were derived using "All," "Returning," and "Persisting" symptomatic definitions. Long-COVID predictors were identified using a multivariate logistic regression model; odds ratios (ORs) and 95% CIs were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Long-COVID subgroups had significantly higher baseline scores for most FLU-PRO Plus domains and Total Score compared with the non-long-COVID group. WPAI:GH and SF-12 Hybrid scores generally showed significantly more impairment for the long-COVID subgroups at baseline and Week 12 vs. the non-long-COVID group. In the univariate analyses, all FLU-PRO Plus domains were significant predictors of long COVID (all <i>p&#x2009;&lt;</i> 0.05), with the exception of the Sense domain. Older age increased the risk of long COVID (OR 1.02, 95% CI 1.00-1.04, <i>p&#x2009;&lt;</i> 0.05). Non-White patients were significantly less likely to have long COVID by the Returning and Persisting definitions vs. White patients (all <i>p&#x2009;&lt;</i> 0.05). In the multivariate analysis, higher scores for the Nose domain (ORs 3.39-5.60, all <i>p&#x2009;&lt;</i> 0.01) and having COPD (ORs 3.75-6.34, all <i>p&#x2009;&lt;</i> 0.05) were significant long-COVID predictors.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Patients who progressed to long COVID had higher symptom severity during the acute disease phase and showed significantly greater negative impact on HRQoL over an extended time period from initial infection through at least the subsequent 3&#x2009;months. The FLU-PRO Plus Nose domain and having COPD were significant predictors of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Gelhorn, Ghafoori, Cutts, Birch, Savva, Satram, Lloyd and Chen.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gelhorn</LastName><ForeName>Heather L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghafoori</LastName><ForeName>Parima</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>GSK, Collegeville, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutts</LastName><ForeName>Katelyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birch</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>GSK, Brentford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savva</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Evidera, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satram</LastName><ForeName>Sacha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vir Biotechnology, Inc., San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lloyd</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GSK, Brentford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen-Hung</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>GSK, Collegeville, PA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">disease predictor</Keyword><Keyword MajorTopicYN="N">health-related quality of life</Keyword><Keyword MajorTopicYN="N">impacts</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword></KeywordList><CoiStatement>HG, KC, and YS are employees of Evidera, which received funding from GSK and Vir Biotechnology, Inc. to conduct this study. PG, HB, EL, and W-HC are employees of, and/or shareholders in, GSK. SS is an employee of, and/or shareholder in, Vir Biotechnology, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>24</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38784592</ArticleId><ArticleId IdType="pmc">PMC11111858</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2024.1278106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270&#x2013;3. doi: 10.1038/s41586-020-2012-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHO coronavirus (COVID-19) dashboard. (2023). Available at:
https://covid19.who.int/ (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>Statista . Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide as of May 2, 2023. (2023). Available at:
https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-worldwide/ (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . Long COVID or post-COVID conditions. (2023). Available at:
https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. (2021) 11:16144. doi: 10.1038/s41598-021-95565-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gennaro F, Belati A, Tulone O, Diella L, Fiore Bavaro D, Bonica R, et al. . Incidence of long COVID-19 in people with previous SARS-Cov2 infection: a systematic review and meta-analysis of 120,970 patients. Intern Emerg Med. (2022) 18:1573&#x2013;81. doi: 10.1007/s11739-022-03164-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-03164-w</ArticleId><ArticleId IdType="pmc">PMC9709360</ArticleId><ArticleId IdType="pubmed">36449260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Deng J, Liu Q, Du M, Liu M, Liu J. Long-term consequences of COVID-19 at 6 months and above: a systematic review and meta-analysis. Int J Environ Res Public Health. (2022) 19:6865. doi: 10.3390/ijerph19116865, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19116865</ArticleId><ArticleId IdType="pmc">PMC9180091</ArticleId><ArticleId IdType="pubmed">35682448</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. . Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. (2021) 27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. (2020) 324:603&#x2013;5. doi: 10.1001/jama.2020.12603, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. . Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. (2020) 15:e0240784. doi: 10.1371/journal.pone.0240784, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. . Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. (2021) 27:258&#x2013;63. doi: 10.1016/j.cmi.2020.09.052, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Bae S, Chang H-H, Kim S-W. Long COVID prevalence and impact on quality of life 2 years after acute COVID-19. Sci Rep. (2023) 13:11207. doi: 10.1038/s41598-023-36995-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-36995-4</ArticleId><ArticleId IdType="pmc">PMC10336045</ArticleId><ArticleId IdType="pubmed">37433819</ArticleId></ArticleIdList></Reference><Reference><Citation>Liska D, Liptakova E, Babicova A, Batalik L, Banarova PS, Dobrodenkova S. What is the quality of life in patients with long COVID compared to a healthy control group? Front Public Health. (2022) 10:975992. doi: 10.3389/fpubh.2022.975992, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.975992</ArticleId><ArticleId IdType="pmc">PMC9667067</ArticleId><ArticleId IdType="pubmed">36408018</ArticleId></ArticleIdList></Reference><Reference><Citation>Velez-Santamaria R, Fernandez-Solana J, Mendez-Lopez F, Dominguez-Garcia M, Gonzalez-Bernal J, Magallon-Botaya R, et al. . Functionality, physical activity, fatigue and quality of life in patients with acute COVID-19 and long COVID infection. Sci Rep. (2023) 13:19907. doi: 10.1038/s41598-023-47218-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-47218-1</ArticleId><ArticleId IdType="pmc">PMC10645778</ArticleId><ArticleId IdType="pubmed">37963962</ArticleId></ArticleIdList></Reference><Reference><Citation>AlRasheed MM, Al-Aqeel S, Aboheimed GI, AlRasheed NM, Abanmy NO, Alhamid GA, et al. . Quality of life, fatigue, and physical symptoms post-COVID-19 condition: a cross-sectional comparative study. Healthcare. (2023) 11:1660. doi: 10.3390/healthcare11111660, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11111660</ArticleId><ArticleId IdType="pmc">PMC10252651</ArticleId><ArticleId IdType="pubmed">37297800</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the longterm effects of COVID-19. (2022). Available at:
https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. (2021). Available at:
https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al. . Symptoms, complications and management of long COVID: a review. J R Soc Med. (2021) 114:428&#x2013;42. doi: 10.1177/01410768211032850, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute COVID-19 in primary care. BMJ. (2020) 370:m3026. doi: 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. (2021) 372:n136. doi: 10.1136/bmj.n136, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, et al. . Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. (2022) 327:1236&#x2013;46. doi: 10.1001/jama.2022.2832, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2832</ArticleId><ArticleId IdType="pmc">PMC8922199</ArticleId><ArticleId IdType="pubmed">35285853</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JH, 3rd, Bacci ED, Guerrero ML, Leidy NK, Stringer S, Kim K, et al. . Reliability, validity, and responsiveness of InFLUenza patient-reported outcome (FLU-PRO&#xa9;) scores in influenza-positive patients. Value Health. (2018) 21:210&#x2013;8. doi: 10.1016/j.jval.2017.04.014, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2017.04.014</ArticleId><ArticleId IdType="pmc">PMC5831548</ArticleId><ArticleId IdType="pubmed">29477403</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JH, Guerrero ML, Leidy NK, Fairchok MP, Rosenberg A, Hern&#xe1;ndez A, et al. . Development of the flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis. (2016) 16:1. doi: 10.1186/s12879-015-1330-0, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1330-0</ArticleId><ArticleId IdType="pmc">PMC4700740</ArticleId><ArticleId IdType="pubmed">26729246</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeley TJH, Satram S, Ghafoori P, Reyes C, Birch HJ, Raymond K, et al. . Content validity and psychometric properties of the in FLUenza patient-reported outcome plus (FLU-PRO plus&#xa9;) instrument in patients with COVID-19. Qual Life Res. (2023) 32:1645&#x2013;57. doi: 10.1007/s11136-022-03336-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-022-03336-3</ArticleId><ArticleId IdType="pmc">PMC9879742</ArticleId><ArticleId IdType="pubmed">36703019</ArticleId></ArticleIdList></Reference><Reference><Citation>Quality Metric . The SF-12v2 PRO health survey. Available at: https://www.qualitymetric.com/health-surveys/the-sf-12v2-pro-health-survey/ (Accessed January 19, 2024).</Citation></Reference><Reference><Citation>Reilly MC. Work productivity and activity impairment questionnaire: general health V2.0 (WPAI:GH 2.0). Available at: https://eprovide.mapi-trust.org/instruments/work-productivity-and-activity-impairment-questionnaire-general-health-v2.0 (Accessed January 19, 2024).</Citation></Reference><Reference><Citation>Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley &amp; Sons, Inc. (2000). 383 p.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsaky T, Graham MS, Penfold RS, Bowyer RC, et al. . Attributes and predictors of long COVID. Nat Med. (2021) 27:626&#x2013;31. doi: 10.1038/s41591-021-01292-y, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, et al. . Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-Centre, population-based cohort study. EClinicalMedicine. (2022) 51:101549. doi: 10.1016/j.eclinm.2022.101549, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101549</ArticleId><ArticleId IdType="pmc">PMC9289961</ArticleId><ArticleId IdType="pubmed">35875815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, Das K, Venkateshan AGM, Mishra B, et al. . Characteristics and predictors of long COVID among diagnosed cases of COVID-19. PLoS One. (2022) 17:e0278825. doi: 10.1371/journal.pone.0278825, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278825</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. . Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: a systematic literature review and meta-analysis. J Clin Med. (2022) 11:7314. doi: 10.3390/jcm11247314, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LD, Ingram J, Sculthorpe NF. More than 100 persistent symptoms of SARS-CoV-2 (long COVID): a scoping review. Front Med. (2021) 8:750378. doi: 10.3389/fmed.2021.750378, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodebaugh TL, Frumkin MR, Reiersen AM, Lenze EJ, Avidan MS, Miller JP, et al. . Acute symptoms of mild to moderate COVID-19 are highly heterogeneous across individuals and over time. Open Forum Infect Dis. (2021) 8:ofab 090. doi: 10.1093/ofid/ofab090, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab090</ArticleId><ArticleId IdType="pmc">PMC7989225</ArticleId><ArticleId IdType="pubmed">33796601</ArticleId></ArticleIdList></Reference><Reference><Citation>Caze AB, Cerqueira-Silva T, Bomfim AP, de Souza GL, Azevedo AC, Brasil MQ, et al. . Prevalence and risk facors for long COVID after mild disease: a cohort study with a symptomatic control group. J Glob Health. (2023) 13:06015. doi: 10.7189/jogh.13.06015, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.13.06015</ArticleId><ArticleId IdType="pmc">PMC10173895</ArticleId><ArticleId IdType="pubmed">37166260</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . National trends in COPD. (2022). Available at:
https://www.cdc.gov/copd/data-and-statistics/national-trends.html (Accessed July 24, 2023).</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. (2022) 28:1706&#x2013;14. doi: 10.1038/s41591-022-01909-w, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>